FDA gives green light to ANDA for chewable diabetes tablet


FDA has approved Boston Therapeutic’s petition to file an Abbreviated New Drug Application (ANDA) for a new, chewable tablet formulation of the diabetes drug metformin hydrochloride. The company plans to market the new formulation under the name Pazamet.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.